möglich sobald bei der ZB eingereicht worden ist.
A20 intrinsically influences human effector T-cell survival and function by regulating both NF-κB and JNK signaling.
Eur. J. Immunol.:e2451245 (2024)
A20 is a dual-function ubiquitin-editing enzyme that maintains immune homeostasis by restraining inflammation. Although A20 serves a similar negative feedback function for T-cell receptor (TCR) signaling, the molecular mechanisms utilized and their ultimate impact on human T-cell function remain unclear. TCR engagement triggers the assembly of the CARD11-BCL10-MALT1 (CBM) protein complex, a signaling platform that governs the activation of downstream transcription factors including NF-κB and c-Jun/AP-1. Utilizing WT and A20 knockout Jurkat T cells, we found that A20 is required to negatively regulate NF-κB and JNK. Utilizing a novel set of A20 mutants in NF-κB and AP-1-driven reporter systems, we discovered the ZnF7 domain is crucial for negative regulatory capacity, while deubiquitinase activity is dispensable. Successful inactivation of A20 in human primary effector T cells congruently conferred sustained NF-κB and JNK signaling, including enhanced upregulation of activation markers, and increased secretion of several cytokines including IL-9. Finally, loss of A20 in primary human T cells resulted in decreased sensitivity to restimulation-induced cell death and increased sensitivity to cytokine withdrawal-induced death. These findings demonstrate the importance of A20 in maintaining T-cell homeostasis via negative regulation of both NF-κB and JNK signaling.
Impact Factor
Scopus SNIP
Altmetric
4.500
0.000
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Apoptosis ; Cellular Immunology ; Cytokines ; Signal Transduction ; T Cells; Transcription Factor Pu.1; Linear Polyubiquitin; Gene-expression; Enzyme A20; Tnfaip3; Binding; Activation; Inhibition; Mutations; Haploinsufficiency
Sprache
englisch
Veröffentlichungsjahr
2024
HGF-Berichtsjahr
2024
ISSN (print) / ISBN
0014-2980
e-ISSN
1521-4141
Zeitschrift
European Journal of Immunology
Quellenangaben
Artikelnummer: e2451245
Verlag
Wiley
Verlagsort
Hoboken
Begutachtungsstatus
Peer reviewed
Institut(e)
Research Unit Signaling and Translation (SAT)
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-509800-001
G-509800-002
G-509800-002
Förderungen
NIH Blood Bank - National Institutes of Health
National Institutes of Health
National Institutes of Health
WOS ID
001324460700001
Scopus ID
85205357891
PubMed ID
39359035
Erfassungsdatum
2024-10-31